Antifungal Agents: Mode of Action, Mechanisms of Resistance, and Correlation of These Mechanisms with Bacterial Resistance
暂无分享,去创建一个
[1] Herbert E. Carter,et al. Protection of fungi against polyene antibiotics by sterols. , 1958, Science.
[2] R. Safferman,et al. MECHANISM OF PROTECTION BY STEROLS AGAINST POLYENE ANTIBIOTICS , 1960, Journal of bacteriology.
[3] W. Zygmunt,et al. Steroid interference with antifungal activity of polyene antibiotics. , 1966, Applied microbiology.
[4] R. Jund,et al. Genetic and Physiological Aspects of Resistance to 5-Fluoropyrimidines in Saccharomyces cerevisiae , 1970, Journal of bacteriology.
[5] R. Moellering,et al. Studies on antibiotic syngerism against enterococci. II. Effect of various antibiotics on the uptake of 14 C-labeled streptomycin by enterococci. , 1971, The Journal of clinical investigation.
[6] R. Moellering,et al. II. EFFECT OF VARIOUS ANTIBIOTICS ON THE UPTAKE OF 4C-LABELED STREPTOMYCIN BY ENTEROCOCCI , 1971 .
[7] H. I. Winner,et al. The development of resistance by candida species to polyene antibiotics in vitro. , 1971, Journal of medical microbiology.
[8] G. Medoff,et al. Synergistic Action of Amphotericin B and 5-Fluorocytosine Against Yeast-Like Organisms 1 , 1971, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[9] S. Normark,et al. In Vitro Studies of 5-Fluorocytosine Resistance in Candida albicans and Torulopsis glabrata , 1972, Antimicrobial Agents and Chemotherapy.
[10] J. Hamilton-miller. Physiological properties of mutagen-induced variants of Candida albicans resistant to polyene antibiotics. , 1972, Journal of medical microbiology.
[11] A. Norman,et al. Studies on the biological properties of polyene antibiotics. Evidence for the direct interaction of filipin with cholesterol. , 1972, The Journal of biological chemistry.
[12] M. Kleinschmidt,et al. Effect of filipin on liposomes prepared with different types of steroids. , 1972, Plant physiology.
[13] A. Norman,et al. Studies on the biological properties of polyene antibiotics: comparison of other polyenes with filipin in their ability to interact specifically with sterol. , 1972, Biochimica et biophysica acta.
[14] R. A. Woods,et al. Polyene resistance and the isolation of sterol mutants in Saccharomyces cerevisiae. , 1972, Journal of general microbiology.
[15] J. Hamilton-miller. Chemistry and Biology of the Polyene Macrolide Antibiotics , 1973, Bacteriological reviews.
[16] D. Feingold,et al. Polyene antibiotic action on lecithin liposomes: effect of cholesterol and fatty acyl chains. , 1973, Biochemical and biophysical research communications.
[17] Chemistry and biology of the polyene macrolide antibiotics. , 1973, Bacteriological reviews.
[18] J. Hamilton-miller. Chemistry and biology of the polyene macrolide antibiotics , 1973, Bacteriological reviews.
[19] E. Grunberg,et al. Chemotherapeutic Activity of 5-Fluorocytosine and Amphotericin B Against Candida albicans in Mice , 1973, Antimicrobial Agents and Chemotherapy.
[20] A. Oehlschlager,et al. Sterol biosynthesis in antibiotic-resistant yeast: nystatin. , 1974, Archives of biochemistry and biophysics.
[21] B. de Kruijff,et al. Polyene antibiotic-sterol interactions in membranes of Acholeplasma laidlawii cells and lecithin liposomes. 3. Molecular structure of the polyene antibiotic-cholesterol complexes. , 1974, Biochimica et biophysica acta.
[22] H. Kropp,et al. THE MECHANISM OF ACTION OF FOSFOMYCIN (PHOSPHONOMYCIN) , 1974, Annals of the New York Academy of Sciences.
[23] R. Holz. THE EFFECTS OF THE POLYENE ANTIBIOTICS NYSTATIN AND AMPHOTERICIN B ON THIN LIPID MEMBRANES , 1974, Annals of the New York Academy of Sciences.
[24] J. Lanyi,et al. Lipid interactions in membranes of extremely halophilic bacteria. II. Modification of the bilayer structure by squalene. , 1974, Biochemistry.
[25] E. Brockman. Mechanisms of Resistance , 1974 .
[26] A. Johnson,et al. Factors affecting the changes in amphotericin sensitivity of Candida albicans during growth. , 1975, Journal of general microbiology.
[27] A. Polak,et al. Mode of action of 5-fluorocytosine and mechanisms of resistance. , 1975, Chemotherapy.
[28] G. Sarosi,et al. Synergistic action of amphotericin B and rifampin against Candida species. , 1976, The Journal of infectious diseases.
[29] P. Traxler,et al. Papulacandins, a new family of antibiotics with antifungal activity, I. Fermentation, isolation, chemical and biological characterization of papulacandins A, B, C, D and E. , 1977, The Journal of antibiotics.
[31] T. Saito,et al. On the mode of action of a new antifungal antibiotic, aculeacin A: inhibition of cell wall synthesis in Saccharomyces cerevisiae. , 1977, The Journal of antibiotics.
[32] J. E. Bennett,et al. Mode of action of 5-fluorocytosine. , 1978, Biochemical pharmacology.
[33] H. van den Bossche,et al. Biochemical effects of miconazole on fungi. II. Inhibition of ergosterol biosynthesis in Candida albicans. , 1978, Chemico-biological interactions.
[34] J. Dubremetz,et al. Ultrastructure of the cell wall of Candida albicans blastospores: study of its constitutive layers by the use of a cytochemical technique revealing polysaccharides. , 1978, Annales de microbiologie.
[35] D. Kerridge,et al. Ultrastructural changes in the cell wall of Candida albicans following cessation of growth and their possible relationship to the development of polyene resistance. , 1979, Journal of general microbiology.
[36] E. Bruck,et al. National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.
[37] W. Merz,et al. Incidence of polyene-resistant yeasts recovered from clinical specimens , 1980, Antimicrobial Agents and Chemotherapy.
[38] D. Lloyd,et al. The Eukaryotic Microbial Cell , 1981 .
[39] D. Kerridge,et al. Lysis of growing yeast-form cells of Candida albicans by echinocandin: a cytological study. , 1981, Sabouraudia.
[40] D. Feingold,et al. Mechanisms of action of the antimycotic imidazoles. , 1981, The Journal of investigative dermatology.
[41] G. Sarosi,et al. Combined action of amphotericin B and 5-fluorocytosine on pathogenic yeasts susceptible to either drug alone. , 1981, Chemotherapy.
[42] D. Stevens,et al. Susceptibility to 5-fluorocytosine and prevalence of serotype in 402 Candida albicans isolates from the United States , 1982, Antimicrobial Agents and Chemotherapy.
[43] R. R. Robinson,et al. Amphotericin B nephrotoxicity: increased renal resistance and tubule permeability. , 1982, Kidney international.
[44] E. S. Beneke,et al. Candida albicans resistance to 5-fluorocytosine: frequency of partially resistant strains among clinical isolates , 1982, Antimicrobial Agents and Chemotherapy.
[45] A. Polak,et al. Combination therapy of experimental candidiasis, cryptococcosis and aspergillosis in mice. , 1982, Chemotherapy.
[46] A. Chopra,et al. Lipids of pathogenic fungi. , 1983, Progress in lipid research.
[47] W. Beggs. Comparison of miconazole- and ketoconazole-induced release of K+ from Candida species. , 1983, The Journal of antimicrobial chemotherapy.
[48] C. Molloy,et al. An analysis of the metabolism and cell wall composition of Candida albicans during germ-tube formation. , 1983, Canadian journal of microbiology.
[49] H. van den Bossche,et al. Hypothesis on the molecular basis of the antifungal activity of N-substituted imidazoles and triazoles. , 1983, Biochemical Society transactions.
[50] D. Kerridge,et al. Decreased activity of UMP pyrophosphorylase associated with resistance to 5-fluorocytosine in Candida albicans , 1984, Antimicrobial Agents and Chemotherapy.
[51] N. Ryder,et al. Effect of the antimycotic drug naftifine on growth of and sterol biosynthesis in Candida albicans , 1984, Antimicrobial Agents and Chemotherapy.
[52] L. J. Nisbet,et al. The effect of aculeacin A and papulacandin B on morphology and cell wall ultrastructure in Candida albicans. , 1984, Canadian journal of microbiology.
[53] R. Prasad,et al. Effect of phospholipid enrichment on nystatin action: differences in antibiotic sensitivity between in vivo and in vitro conditions. , 1985, Microbios.
[54] R. Prasad,et al. Phospholipid enrichment of Saccharomyces cerevisiae and its effect on polyene sensitivity. , 1985, Canadian journal of microbiology.
[55] G. Medoff,et al. Sensitivity of Candida albicans to amphotericin B administered as single or fractionated doses , 1986, Antimicrobial Agents and Chemotherapy.
[56] J. V. van Cutsem,et al. Azole resistance in Candida albicans. , 1986, Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology.
[57] N. Russell,et al. The lipid composition and permeability to azole of an azole- and polyene-resistant mutant of Candida albicans. , 1987, Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology.
[58] R. Juliano,et al. Mechanism of the selective toxicity of amphotericin B incorporated into liposomes. , 1987, Molecular pharmacology.
[59] W. Whelan. The genetic basis of resistance to 5-fluorocytosine in Candida species and Cryptococcus neoformans. , 1987, Critical reviews in microbiology.
[60] L. Liu,et al. In‐vivo studies of amphotericin B liposomes derived from proliposomes: effect of formulation on toxicity and tissue disposition of the drug in mice , 1987, The Journal of pharmacy and pharmacology.
[61] L. Frankel,et al. Treatment of hepatosplenic candidiasis with liposomal-amphotericin B. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[62] J. Barber,et al. Fatal disseminated cryptococcosis following intraocular involvement. , 1988, The British journal of ophthalmology.
[63] P. Gopal,et al. Evidence for a glycosidic linkage between chitin and glucan in the cell wall of Candida albicans. , 1988, Journal of general microbiology.
[64] R F Woolson,et al. Hospital-acquired candidemia. The attributable mortality and excess length of stay. , 1988, Archives of internal medicine.
[65] V. Wiebe,et al. Liposome-encapsulated amphotericin B: a promising new treatment for disseminated fungal infections. , 1988, Reviews of infectious diseases.
[66] C. Bizet,et al. In vivo selection of a cephamycin-resistant, porin-deficient mutant of Klebsiella pneumoniae producing a TEM-3 beta-lactamase. , 1989, The Journal of infectious diseases.
[67] G. Khuller,et al. Influence of lipid composition on the sensitivity of Candida albicans to antifungal agents. , 1989, Indian journal of biochemistry & biophysics.
[68] E. Anaissie,et al. Nosocomial fungal infections. Old problems and new challenges. , 1989, Infectious disease clinics of North America.
[69] David John Adams,et al. Interaction of azole antifungal antibiotics with cytochrome P-450-dependent 14 alpha-sterol demethylase purified from Candida albicans. , 1990, The Biochemical journal.
[70] S. Levy. Starting life resistance-free. , 1990, The New England journal of medicine.
[71] H. Gallis,et al. Amphotericin B: 30 years of clinical experience. , 1990, Reviews of infectious diseases.
[72] T. Walsh,et al. Antifungal effects of the nonlinear pharmacokinetics of cilofungin, a 1,3-beta-glucan synthetase inhibitor, during continuous and intermittent intravenous infusions in treatment of experimental disseminated candidiasis , 1991, Antimicrobial Agents and Chemotherapy.
[73] G. Hunter,et al. In vitro and in vivo characterization of herpes simplex virus clinical isolates recovered from patients infected with human immunodeficiency virus , 1991, Antimicrobial Agents and Chemotherapy.
[74] Mitchell L. Cohen. Epidemiology of Drug Resistance: Implications for a Post—Antimicrobial Era , 1992, Science.
[75] J. Tkacz. Glucan Biosynthesis in Fungi and its Inhibition , 1992 .
[76] N. Georgopapadakou,et al. Emerging Targets in Antibacterial and Antifungal Chemotherapy , 2012, Springer US.
[77] D. Livermore. Interplay of impermeability and chromosomal beta-lactamase activity in imipenem-resistant Pseudomonas aeruginosa , 1992, Antimicrobial Agents and Chemotherapy.
[78] J. Duval,et al. Resistance of enterococci to aminoglycosides and glycopeptides. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[79] F. Odds,et al. Characterization of an azole-resistant Candida glabrata isolate , 1992, Antimicrobial Agents and Chemotherapy.
[80] C. Higgins,et al. ABC transporters: from microorganisms to man. , 1992, Annual review of cell biology.
[81] S. Levy,et al. Genetic and functional analysis of the multiple antibiotic resistance (mar) locus in Escherichia coli , 1993, Journal of bacteriology.
[82] C. Roessner,et al. Sequence of the Candida albicans erg7 gene. , 1993, Gene.
[83] P. Marichal,et al. Effects of itraconazole on cytochrome P-450-dependent sterol 14 alpha-demethylation and reduction of 3-ketosteroids in Cryptococcus neoformans , 1993, Antimicrobial Agents and Chemotherapy.
[84] D I Edwards,et al. Nitroimidazole drugs--action and resistance mechanisms. II. Mechanisms of resistance. , 1993, The Journal of antimicrobial chemotherapy.
[85] G. Kaatz,et al. Fluoroquinolone resistance protein NorA of Staphylococcus aureus is a multidrug efflux transporter , 1993, Antimicrobial Agents and Chemotherapy.
[86] C. Beck-Sague,et al. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. , 1993, The Journal of infectious diseases.
[87] I. Pastan,et al. Biochemistry of multidrug resistance mediated by the multidrug transporter. , 1993, Annual review of biochemistry.
[88] D I Edwards,et al. Nitroimidazole drugs--action and resistance mechanisms. I. Mechanisms of action. , 1993, The Journal of antimicrobial chemotherapy.
[89] E. Anaissie,et al. Experimental hematogenous candidiasis caused by Candida krusei and Candida albicans: species differences in pathogenicity , 1993, Infection and immunity.
[90] R. Fromtling,et al. Cutaneous antifungal agents : selected compounds in clinical practice and development , 1993 .
[91] R. Hector,et al. Compounds active against cell walls of medically important fungi , 1993, Clinical Microbiology Reviews.
[92] N. Georgopapadakou,et al. Human mycoses: drugs and targets for emerging pathogens. , 1994, Science.
[93] S. Kelly,et al. Resistance to amphotericin B associated with defective sterol delta 8-->7 isomerase in a Cryptococcus neoformans strain from an AIDS patient. , 1994, FEMS microbiology letters.
[94] A. Casadevall,et al. Sterol composition of Cryptococcus neoformans in the presence and absence of fluconazole , 1994, Antimicrobial Agents and Chemotherapy.
[95] J. McCutchan,et al. Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[96] D. Livermore,et al. Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: active efflux as a contributing factor to beta-lactam resistance , 1994, Antimicrobial Agents and Chemotherapy.
[97] B. Spratt,et al. Origin and molecular epidemiology of penicillin-binding-protein-mediated resistance to beta-lactam antibiotics. , 1994, Trends in microbiology.
[98] L. Gutmann,et al. beta-lactamase inhibitors . beta-lactamase conferring resistance to coli producing TEM-1 derivatives or an OXA-1 Emergence of clinical isolates of Escherichia , 1994 .
[99] M. Pfaller,et al. Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[100] G. Satta,et al. Overproduction of a low-affinity penicillin-binding protein and high-level ampicillin resistance in Enterococcus faecium , 1994, Antimicrobial Agents and Chemotherapy.
[101] L. Samaranayake,et al. Candida krusei: biology, epidemiology, pathogenicity and clinical manifestations of an emerging pathogen. , 1994, Journal of medical microbiology.
[102] K. Kuchler,et al. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters , 1995, Antimicrobial agents and chemotherapy.
[103] J. Swartz,et al. Deletion of the Candida glabrata ERG3 and ERG11 genes: effect on cell viability, cell growth, sterol composition, and antifungal susceptibility , 1995, Antimicrobial agents and chemotherapy.
[104] T. Kocagoz,et al. Point mutations in Staphylococcus aureus PBP 2 gene affect penicillin-binding kinetics and are associated with resistance , 1995, Antimicrobial agents and chemotherapy.
[105] S. Michaelis,et al. Sequence comparison of yeast ATP-binding cassette proteins. , 1995, Cold Spring Harbor symposia on quantitative biology.
[106] J. Rex,et al. Resistance of Candida species to fluconazole , 1995, Antimicrobial agents and chemotherapy.
[107] T. Parkinson,et al. Fluconazole resistance due to energy-dependent drug efflux in Candida glabrata , 1995, Antimicrobial agents and chemotherapy.
[108] L. Gutmann,et al. Structure of the low-affinity penicillin-binding protein 5 PBP5fm in wild-type and highly penicillin-resistant strains of Enterococcus faecium , 1996, Journal of bacteriology.
[109] J. Rex,et al. Resistance to antifungal agents in the critical care setting: problems and perspectives. , 1996, New horizons.
[110] N. Gow,et al. Correlation between rhodamine 123 accumulation and azole sensitivity in Candida species: possible role for drug efflux in drug resistance , 1996, Antimicrobial agents and chemotherapy.
[111] T J Walsh,et al. Antifungal agents: chemotherapeutic targets and immunologic strategies , 1996, Antimicrobial agents and chemotherapy.
[112] Activity of KRM-1648 alone or in combination with both ethambutol and kanamycin or clarithromycin against Mycobacterium intracellulare infections in beige mice , 1996, Antimicrobial agents and chemotherapy.
[113] H. Jenkinson. Ins and Outs of Antimicrobial Resistance: Era of the Drug Pumps , 1996, Journal of dental research.
[114] P. Courvalin,et al. Glycopeptide resistance in enterococci. , 1996, Trends in microbiology.
[115] R. Haubrich,et al. Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: the role of antifungal susceptibility testing. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[116] D. Sanglard,et al. Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors , 1996, Antimicrobial agents and chemotherapy.
[117] D. Bryant,et al. Peptidoglycan synthesis and structure in Staphylococcus haemolyticus expressing increasing levels of resistance to glycopeptide antibiotics , 1996, Journal of bacteriology.
[118] T. C. White,et al. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus , 1997, Antimicrobial agents and chemotherapy.
[119] M. Ghannoum,et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Labora , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[120] Brian C. Baldwin,et al. The Mutation T315A in Candida albicans Sterol 14α-Demethylase Causes Reduced Enzyme Activity and Fluconazole Resistance through Reduced Affinity* , 1997, The Journal of Biological Chemistry.
[121] D. Landsman,et al. New evidence that Candida albicans possesses additional ATP-binding cassette MDR-like genes: implications for antifungal azole resistance. , 1997, Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology.
[122] M. Ghannoum,et al. A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei , 1997, Antimicrobial agents and chemotherapy.
[123] D. Gerding,et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance Guidelines for the Prevention of Antimicrobial Resistance in Hospitals , 1997, Infection Control & Hospital Epidemiology.
[124] T. C. White,et al. The presence of an R467K amino acid substitution and loss of allelic variation correlate with an azole-resistant lanosterol 14alpha demethylase in Candida albicans , 1997, Antimicrobial agents and chemotherapy.
[125] M. Ghannoum,et al. Voriconazole (UK-109,496) inhibits the growth and alters the morphology of fluconazole-susceptible and -resistant Candida species , 1997, Antimicrobial agents and chemotherapy.
[126] C. Douglas,et al. Lipopeptide inhibitors of fungal glucan synthase. , 1997, Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology.
[127] D. Gerding,et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. , 1997, Infection control and hospital epidemiology.
[128] A. Espinel-Ingroff. Clinical relevance of antifungal resistance. , 1997, Infectious disease clinics of North America.
[129] M. Ghannoum,et al. Mechanism of Fluconazole Resistance inCandida krusei , 1998, Antimicrobial Agents and Chemotherapy.
[130] J. Graybill,et al. Fluconazole versus Candida albicans: A Complex Relationship , 1998, Antimicrobial Agents and Chemotherapy.
[131] P. Loiseau,et al. Mechanism of Amphotericin B Resistance inLeishmania donovani Promastigotes , 1998, Antimicrobial Agents and Chemotherapy.
[132] T. C. White,et al. Clinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance , 1998, Clinical Microbiology Reviews.
[133] B. Kullberg,et al. Guidelines for the prevention of antimicrobial resistance in hospitals. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[134] J. Acar,et al. Rapid emergence of resistance to cefepime during treatment. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[135] D. Sheehan,et al. Current and Emerging Azole Antifungal Agents , 1999, Clinical Microbiology Reviews.
[136] M. Ghannoum,et al. Antifungal activity of voriconazole (UK-109,496), fluconazole and amphotericin B against hematogenous Candida krusei infection in neutropenic guinea pig model. , 1999, Journal of chemotherapy.
[137] Effects of Cilofungin ( LYI 21019 ) on Carbohydrate and Sterol Composition of Candida albicans , .